Rs 500 Crore Capex Boost: This Pharma Stock Begins A New Growth Chapter

IOL Chemicals and Pharmaceuticals is stepping up investment in its core Ibuprofen franchise while moving into formulations contract manufacturing, announcing growth projects worth about Rs 500 crore that could add 25 per cent to 30 per cent to revenue by FY29 once fully operational and utilised.

The investment package includes a Rs 350 crore expansion of Ibuprofen capacity, a formulations CDMO facility and a specialty chemicals unit operating under a long-term tolling arrangement with a global chemical company. The company said around 30 per cent of the overall funding requirement, or roughly Rs 150 crore based on the announced outlay, has already been incurred. The projects will be funded through internal accruals.

The largest component is a 6,000 metric tonnes per annum Ibuprofen capacity addition, which will lift IOL’s total capacity to 18,000 MTPA from 12,000 MTPA. That represents a 50 per cent increase in the company’s Ibuprofen manufacturing capacity, at a time when its existing facilities are operating at 90 per cent to 95 per cent utilisation.

The new fully backward-integrated Ibuprofen facility is expected to be commissioned by December 2027. Management expects the expansion to start at about 25 per cent utilisation in FY28 and move towards optimal utilisation of more than 80 per cent during FY28-29. At peak utilisation, it has indicated revenue potential of around 1.75 times the investment, although it cautioned that realisations will depend on customer mix, geography, contracts and market conditions.
Also Read - 12-Year Wait Ends: EPFO Salary Limit Gets A Massive Rs 10,000 Jump

The decision is significant because Ibuprofen remains central to IOL’s pharmaceutical business, even as the company has been diversifying into other APIs. The company had earlier said its non-Ibuprofen APIs accounted for 37 per cent of pharmaceutical revenue in FY26, up from 18 per cent in FY21. The fresh expansion suggests that diversification is being pursued alongside, rather than instead of, a larger core Ibuprofen platform.

Management said Ibuprofen prices have remained broadly stable in recent months after earlier war-related price movements. It added that backward integration could support probable margin expansion if input costs soften while product prices remain steady. Long-term contracts also contain price-adjustment clauses for movements beyond specified levels, providing some protection from raw-material volatility.

The second project marks IOL’s entry into formulations CDMO, or contract development and manufacturing. Its new EU GMP-certified facility can produce about 1,500 million tablets a year, or equivalent Direct Compressible Grade volumes. Commercialisation is expected in the third quarter of FY27, while full operationalisation is targeted in the following financial year.

The CDMO facility is aimed mainly at established European customers that have asked IOL to supply bulk tablets instead of only APIs. The company will initially work with existing customers and products rather than launch finished formulations under its own brand. Contracts are expected to resemble its API arrangements, generally spanning three to five years and including escalation provisions.

At around 90 per cent utilisation, IOL expects a CDMO asset turn of roughly 1x to 1.25x. Management expects CDMO margins to be higher than API margins but has not quantified the likely improvement. Customer approvals, product development and the speed of commercial ramp-up will remain key variables.

The third initiative is a dedicated specialty chemicals facility for a product not currently in IOL’s portfolio. It will operate under a long-term tolling arrangement with a leading global chemical company, giving the project relatively clearer demand visibility than a conventional merchant chemical launch.

The announced projects are separate from IOL’s earlier Rs 1,200 crore to Rs 1,400 crore greenfield plan at a site around 25 to 30 kilometres from its existing plant. The company said most approvals for that project have been obtained and initial groundwork has begun.

The expansion comes after a stronger latest reported quarter, when net sales rose 37.08 per cent year-on-year to Rs 756.26 crore and profit after Tax increased 89.8 per cent to Rs 64.40 crore. As of 3:33 pm on September 17, 2026, the stock was trading at Rs 197.15, up 1.81 per cent from the previous close. The share price has gained 99.78 per cent over one year, compared with a 2.65 per cent decline in the BSE 500, and was about 7.5 per cent below its 52-week high of Rs 213.05.

About the company:
IOL Chemicals and Pharmaceuticals Ltd is a Ludhiana-based pharmaceutical and chemical company engaged in the manufacturing of active pharmaceutical ingredients (APIs) and specialty chemicals. The company has a strong presence in Ibuprofen and other APIs, supported by backward integration capabilities across key products. It also operates in specialty chemicals and is expanding into formulations CDMO and customer-led chemical manufacturing solutions.

Disclaimer: The article is for informational purposes only and not investment advice.